1. Clinical Developments in Inflammatory Arthritis 2017

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction Psoriatic Arthritis

4. Treatment of Psoriatic Arthritis The Pathophysiologic Cascade

5. Treating and Managing Psoriatic Arthritis

6. Introduction to Rheumatoid Arthritis

7. Management of RA With DMARDs

8. Updates on JAK Inhibitors for the Treatment of Rheumatoid Arthritis

9. Long-Term Safety of Baricitinib for the Treatment of RA (5.5 Years)

10. Pain Control With Baricitinib and Methotrexate in DMARD-Naive Patients

11. Safety and Efficacy of Tofacitinib ORAL Strategy

12. Upadacitinib in Patients With Inadequate Response to csDMARDs

13. Upadacitinib in Patients With Inadequate Response or Intolerance to Biological DMARDs

14. What's New in Therapies for Rheumatoid Arthritis?

15. Impact of Adalimumab on Prednisone Use

16. CV Safety of Tocilizumab vs Abatacept in Patients With RA

17. Sustained Response After Discontinuation of MTX in Patients Treated With SC Tocilizumab

18. Sustained Response After Discontinuation of MTX in Patients Treated With SC Tocilizumab (cont)

19. Discontinuation of MTX for 2 Weeks Improves Immunogenicity of Seasonal Influenza Vaccination

20. Updates on Treatments in Psoriatic Arthritis

21. Efficacy and Safety of Abatacept Results From the ASTRAEA Study

22. Radiographic Progression of Structural Joint Damage With Ixekizumab in SPIRIT-P1

23. Efficacy and Safety of Ixekizumab in Patients With Inadequate Response to TNFi: SPIRIT-P2

24. Safety and Efficacy of Guselkumab Phase 2a RCT (24 Week and 56 Week)

25. Monitoring Disease Activity in PsA

26. Treatment and Management of PsA

27. What's New in Therapies for PsA?

28. Inhibition of Radiographic Progression in Active PsA by Adalimumab

29. Efficacy and Safety of Golimumab at Week 24 GO-VIBRANT Study

30. Inhibition of Radiographic Progression by SC Secukinumab

31. OPAL BROADEN Use of Tofacitinib in Patients With PsA

32. OPAL BEYOND Use of Tofacitinib in Patients With PsA

33. Apremilast Monotherapy in Biologic-Naive Patients With Active PsA: ACTIVE Trial

34. Abbreviations

35. Abbreviations (cont)

36. Abbreviations (cont)

37. Abbreviations (cont)